U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT06885021) titled 'Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults' on March 13.
Brief Summary: A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
Study Start Date: March 28
Study Type: INTERVENTIONAL
Condition:
Overweight and Obesity
Intervention:
DRUG: HDM1002 200mg, oral, once daily, 52 weeks
HDM1002 200mg, oral, once daily, 52 weeks
DRUG: HDM1002 400mg, oral, once daily, 52 weeks
HDM1002 400mg, oral, once daily, 52 weeks
DRUG: HDM1002 placebo, oral, once daily, 52 weeks
HDM1002 placebo, oral, once daily, 52 weeks
Recruitment Status: NOT_YET_R...